Adlai Nortye (ANL)

Monday

9:45 AM

ThesisRecent positive sentiment in the biotech sector, coupled with promising clinical trial results, has led to increased investor interest in Adlai Nortye.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$5M	$18M	$10M
Rev. Growth	—	+254%	-43.5%
EPS	$-3.33	$-0.17	$-0.28
EPS Growth	+31.9%	+94.9%	-62.4%
P/E	—	—	—

★ Analysts see FY2026 revenue reaching $18M — +254% growth in a single year.

Why Revenue Could Explode

01Positive Phase II trial results for AND-139 could lead to a significant increase in stock price, potentially doubling market cap.
02Potential licensing agreement with a major pharmaceutical company for AND-139 could provide $50M upfront payment.
03Increased investor interest in oncology biotech stocks could drive up valuations across the sector, benefiting Adlai Nortye.
04Growing demand for targeted cancer therapies
05Increased investment in biotech R&D
06Progress in clinical trials for AND-139, particularly Phase II results
07Partnership announcements for drug development or commercialization
08Regulatory approvals from health authorities in key markets

FY2025 Snapshot

Revenue: $5M
Gross Margin: 100%
Op. Margin: -714%
Net Margin: -711%
Net Income: $-36M
NI Growth: +31.5%
EPS: $-3.33
1Y Return: +720%

My Notes

"Investors are eager to see how AND-139 performs in upcoming trials."
Moat: Adlai Nortye's focus on targeted therapies in oncology provides a competitive edge, but the moat is vulnerable to rapid innovation.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
Interest rates affect the cost of capital for R&D funding and can influence investor sentiment towards biotech valuations…
Watch on earnings: Clinical trial progress for AND-139, Cash runway (months until funding is needed), Market reaction to biotech sector performance.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $18M to $10M as positive phase ii trial results for and-139 could lead to a significant increase in stock price.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.